PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate developments.
Related news for (PEPG)
- 24/7 Market News Snapshot 25 September, 2025 – PepGen Inc. Common Stock (NASDAQ:PEPG)
- PepGen Announces Pricing of $100 Million Public Offering
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/25/25 07:00 AM
- Today’s Top Performers: MoBot’s Market Review 09/25/25 06:00 AM
- MoBot alert highlights: NASDAQ: OFAL, NASDAQ: PEPG, NASDAQ: XXII, NYSE: LAC, NYSE: ATCH (09/25/25 05:00 AM)